← Leaderboards
Peter Leif Bergsagel
Weill Medical College Of Cornell Univ
$19,500,560
Attributed
$20,770,141
Total exposure
21
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$46,055,223 · 23
By mechanism
P50$28,297,018 · 8
R01$10,550,417 · 6
U54$5,778,017 · 6
UG3$704,622 · 1
R56$405,078 · 1
K01$320,071 · 1
Top collaborators
- Marta Chesi4 shared
- Shaji Kunnathu Kumar1 shared
- Nathalie Meurice1 shared
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
Research focus
Multiple MyelomaGeneticCellsResponseMutationClinicMalignant NeoplasmsTumorSamplingPharmaceutical PreparationsMalignant - DescriptorPlasma CellsBaseReportingMouse ModelRelapseResearch PersonnelBone MarrowIn VivoClinical TrialsPathway InteractionsEventDrug ResistanceAffect
Grant awards (82)
Mayo Clinic Multiple Myeloma SPORE$2,224,423
P50 · FY2025 · CA · contact PI
Preclinical studies for the immunoprevention of multiple myeloma$704,622
UG3 · FY2025 · CA · contact PI
preclinical optimization of BCMA directed T cell therapy$621,878
R01 · FY2025 · CA
Administrative Core$130,826
P50 · FY2025 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$2,098,348
P50 · FY2024 · CA · contact PI
preclinical optimization of BCMA directed T cell therapy$590,784
R01 · FY2024 · CA
Administrative Core$123,503
P50 · FY2024 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$1,976,442
P50 · FY2023 · CA · contact PI
preclinical optimization of BCMA directed T cell therapy$621,878
R01 · FY2023 · CA
Administrative Core$120,487
P50 · FY2023 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$2,031,615
P50 · FY2022 · CA · contact PI
Project 3: Early detection and prevention of MM progression$337,306
P50 · FY2022 · CA · contact PI
Administrative Core$120,363
P50 · FY2022 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$2,091,215
P50 · FY2021 · CA · contact PI
Overcoming Drug Resistance in Multiple Myeloma$982,082
U54 · FY2021 · CA · contact PI
Project 3: Early detection and prevention of MM progression$396,805
P50 · FY2021 · CA · contact PI
Project 1 - High Throughtput Drug Screening and Correlations with Mutational Status in Myeloma Cell Lines and Patient Samples$314,462
U54 · FY2021 · CA · contact PI
Administrative Core$121,465
P50 · FY2021 · CA · contact PI
Overcoming Drug Resistance in Multiple Myeloma$83,332
U54 · FY2021 · CA · contact PI
Admin Core$83,332
U54 · FY2021 · CA · contact PI
Admin Core$65,461
U54 · FY2021 · CA · contact PI
Overcoming Drug Resistance in Multiple Myeloma$1,180,311
U54 · FY2020 · CA · contact PI
Mutations that Distinguish Benign from Malignant Plasma Cell Neoplasams$379,725
R01 · FY2020 · CA · contact PI
Admin Core$83,665
U54 · FY2020 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$2,120,249
P50 · FY2019 · CA · contact PI
Overcoming Drug Resistance in Multiple Myeloma$1,311,568
U54 · FY2019 · CA · contact PI
Project 2 - IMiD Resistance in Patients and Humanized Mice with Multiple Myeloma$391,500
U54 · FY2019 · CA · contact PI
Mutations that Distinguish Benign from Malignant Plasma Cell Neoplasams$368,332
R01 · FY2019 · CA · contact PI
Project 3 - Modeling Proteasome Inhibitor Response and Resistance in Cell Lines and Patient Samples with Single Cell Analysis of Subpopulations$365,497
U54 · FY2019 · CA · contact PI
Oncolytic Virotherapy for Multiple Myeloma using VSV$356,866
P50 · FY2019 · CA · contact PI
MYC in the Progression and Treatment of Multiple Myeloma$267,051
P50 · FY2019 · CA · contact PI
Admin Core$163,071
U54 · FY2019 · CA · contact PI
Administrative Core$104,820
P50 · FY2019 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$2,538,499
P50 · FY2018 · CA · contact PI
Oncolytic Virotherapy for Multiple Myeloma using VSV$403,338
P50 · FY2018 · CA · contact PI
Mutations that Distinguish Benign from Malignant Plasma Cell Neoplasams$379,725
R01 · FY2018 · CA · contact PI
MYC in the Progression and Treatment of Multiple Myeloma$313,523
P50 · FY2018 · CA · contact PI
Administrative Core$151,293
P50 · FY2018 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$2,299,999
P50 · FY2017 · CA · contact PI
Project 2 - IMiD Resistance in Patients and Humanized Mice with Multiple Myeloma$753,736
U54 · FY2017 · CA · contact PI
Oncolytic Virotherapy for Multiple Myeloma using VSV$383,221
P50 · FY2017 · CA · contact PI
Mutations that Distinguish Benign from Malignant Plasma Cell Neoplasams$379,725
R01 · FY2017 · CA · contact PI
MYC in the Progression and Treatment of Multiple Myeloma$288,679
P50 · FY2017 · CA · contact PI
Administrative Core$117,910
P50 · FY2017 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$2,161,999
P50 · FY2016 · CA · contact PI
Mutations that Distinguish Benign from Malignant Plasma Cell Neoplasams$379,725
R01 · FY2016 · CA · contact PI
Oncolytic Virotherapy for Multiple Myeloma using VSV$354,228
P50 · FY2016 · CA · contact PI
MYC in the Progression and Treatment of Multiple Myeloma$269,800
P50 · FY2016 · CA · contact PI
Administrative Core$117,306
P50 · FY2016 · CA · contact PI
Mayo Clinic Multiple Myeloma SPORE$2,185,000
P50 · FY2015 · CA · contact PI
Oncolytic Virotherapy for Multiple Myeloma using VSV$358,697
P50 · FY2015 · CA · contact PI
Inhibiting MYC for the Treatment of Multiple Myeloma$347,976
R01 · FY2015 · CA · contact PI
MYC in the Progression and Treatment of Multiple Myeloma$273,207
P50 · FY2015 · CA · contact PI
Administrative Core$114,501
P50 · FY2015 · CA · contact PI
Mouse Model of Age-Associated Monoclonal Gammopathy$314,838
R01 · FY2014 · AG · contact PI
Comparative Pharmaco-oncogenomics of Myeloma Drug Resistance$302,718
R01 · FY2013 · CA · contact PI
Molecular Pathogenesis of Multiple Myeloma$302,718
R01 · FY2013 · CA · contact PI
Mouse Model of Age-Associated Monoclonal Gammopathy$297,522
R01 · FY2013 · AG · contact PI
Molecular Pathogenesis of Multiple Myeloma$322,040
R01 · FY2012 · CA · contact PI
Comparative Pharmaco-oncogenomics of Myeloma Drug Resistance$322,040
R01 · FY2012 · CA · contact PI
Mouse Model of Age-Associated Monoclonal Gammopathy$317,782
R01 · FY2012 · AG · contact PI
P-4: Targeting activation of NFkB pathways in MM$283,044
P50 · FY2012 · CA · contact PI
Molecular Pathogenesis of Multiple Myeloma$322,040
R01 · FY2011 · CA · contact PI
Comparative Pharmaco-oncogenomics of Myeloma Drug Resistance$322,040
R01 · FY2011 · CA · contact PI
Mouse Model of Age-Associated Monoclonal Gammopathy$319,278
R01 · FY2011 · AG · contact PI
P-4: Targeting activation of NFkB pathways in MM$272,300
P50 · FY2011 · CA · contact PI
Mouse Model of Age-Associated Monoclonal Gammopathy$332,166
R01 · FY2010 · AG · contact PI
Comparative Pharmaco-oncogenomics of Myeloma Drug Resistance$332,000
R01 · FY2010 · CA · contact PI
Molecular Pathogenesis of Multiple Myeloma$332,000
R01 · FY2010 · CA · contact PI
P-4: Targeting activation of NFkB pathways in MM$287,967
P50 · FY2010 · CA · contact PI
Mouse Models of Age-Associated Monoclonal Gammopathy$405,078
R56 · FY2009 · AG · contact PI
Molecular Pathogenesis of Multiple Myeloma$332,000
R01 · FY2009 · CA · contact PI
Comparative Pharmaco-oncogenomics of Myeloma Drug Resistance$332,000
R01 · FY2009 · CA · contact PI
P-4: Targeting activation of NFkB pathways in MM$289,170
P50 · FY2009 · CA · contact PI
P-4: Targeting activation of NFkB pathways in MM$211,553
P50 · FY2008 · CA · contact PI
Mouse models of age-associated monoclonal gammopathy$296,557
R01 · FY2007 · AG · contact PI
Mouse models of age-associated monoclonal gammopathy$305,415
R01 · FY2006 · AG · contact PI
Mouse models of age-associated monoclonal gammopathy$312,765
R01 · FY2005 · AG
Mouse models of age-associated monoclonal gammopathy$381,375
R01 · FY2004 · AG
Mouse models of age-associated monoclonal gammopathy$381,375
R01 · FY2003 · AG
MOLECULAR PATHOGENESIS OF PLASMA CELL NEOPLASMS$160,920
K01 · FY2001 · CA
MOLECULAR PATHOGENESIS OF PLASMA CELL NEOPLASMS$159,151
K01 · FY2000 · CA